Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis

American Journal of Respiratory and Critical Care Medicine

Volumn 160, Issue 1, 1999, Pages 192-197

  Baltzan, Marcel ^a   Mehta, Sanjay ^a   Kirkham, Trevor H ^a   Cosio, Manuel G ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CHLOROQUINE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE; METHOTREXATE; PHENYLBUTAZONE; PREDNISONE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG INDUCED DISEASE; ENZYME BLOOD LEVEL; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; LUNG FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SARCOIDOSIS; TINNITUS; TREATMENT OUTCOME; VERTIGO; VISUAL IMPAIRMENT;

EID: 0032795221     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.160.1.9809024     Document Type: Article

References (35)

1. Neville, E., A. N. Walker, and D. G. James. 1983. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q. J. Med. 208:525-533.
2. Sharma, O. P., and S. Alam. 1995. Diagnosis, pathogenesis and treatment of sarcoidosis. Curr. Opin. Pulm. Med. 1:392-400.
3. James, D. G., L. S. Carstairs, J. Trowell, and O. P. Sharma. 1967. Treatment of sarcoidosis: report of a controlled therapeutic trial. Lancet 2:526-528.
4. Hunninghake, G. W., S. Gilbert, R. Pueringer, C. Dayton, C. Florechinger, R. Helmers, R. Merchant, J. Wilson, J. Galvin, and D. Schwartz. 1994. Outcome of the treatment for sarcoidosis. Am. J. Respir. Crit. Care Med. 149:893-898.
5. Gibson, G. J., R. J. Prescott, M. F. Muers, W. G. Middleton, D. N. Mitchell, C. K. Connolly, and B. D. W. Harrison. 1996. British Thoracic Society sarcoidosis study: effect of long-term corticosteroid treatment. Thorax 51:238-247.
6. Johns, C. J., S. A. Schonfeld, P. P. Scott, J. B. Zachary, and M. I. MacGregor. 1986. Longitudinal study of chronic sarcoidosis with low dose maintenance corticosteroid therapy: outcome and complications. Ann. N.Y. Acad. Sci. 465:702-712.
7. Zic, J. A., D. H. Horowitz, C. Arzubiaga, and L. E. King. 1991. Treatment of cutaneous sarcoidosis with chloroquine. Arch. Dermatol. 127: 1034-1040.
8. Davies, D. 1963. Sarcoidosis treated by chloroquine. Br. J. Dis. Chest 57:30-36.
9. Hirsch, J. G. 1961. Experimental treatment with chloroquine. Am. Rev. Respir. Dis. 84:52-58.
10. Krasnitz, A. 1967. Chloroquine therapy in pulmonary sarcoidosis. N.Y. State J. Med. 67:1729-1736.
11. Siltzbach, L. E., and A. S. Tierstein. 1964. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med. Scand. Suppl. 425:302-307.
12. Morse, S. I., Z. A. Cohn, J. G. Hirsch, and R. W. Shaedler. 1961. The treatment of sarcoidosis with chloroquine. Am. J. Med. 30:779-784.
13. British Tuberculosis Association. 1967. Chloroquine in the treatment of sarcoidosis. Tubercle 48:257-272.
14. Crapo, R. O., A. H. Morris, and R. M. Gardner. 1981. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am. Rev. Respir. Dis. 123:659-664.
15. American Thoracic Society. 1987. Standardization of spirometry - 1987 update. Am. Rev. Respir. Dis. 136:1285-1298.
16. American Thoracic Society. 1995. Single-breath carbon monoxide diffusing capacity (transfer factor): recommendations for a standard technique - 1995 update. Am. J. Respir. Crit. Care Med. 152:2185-2198.
17. Renzetti, A. D., Jr., E. R. Bleeker, G. R. Epler, R. N. Jones, R. E. Kanner, and L. H. Repsher. 1986. Evaluation of impairment/disability secondary to respiratory disorders. Am. Rev. Respir. Dis. 13:1205-1209.
18. Armitage, P., and G. Berry. 1994. Statistical Methods in Medical Research, 3rd ed. Blackwell Science, Oxford. 93-153.
19. Ware, J. H., and S. Weiss. 1996. Statistical issues in longitudinal research on respiratory health. Am. J. Respir. Crit. Care Med. 154:S212-216.
20. Cox, D. R., and D. Oakes. 1984. Analysis of Survival Data. Chapman & Hall, London. 124.
21. Fletcher, C., R. Peto, C. Tinker, and F. E. Speizer. 1976. The Natural History of Chronic Bronchitis and Emphysema: An Eight Year Study of Early Chronic Obstructive Lung Disease in Working Men in London. Oxford University Press, Oxford. 62-89.
22. Siltzbach, L. E., D. G. James, E. Neville, J. Turiaf, J. P. Battesti, O. P. Sharma, Y. Hosada, R. Mikami, and M. Odaka. 1974. Course and prognosis of sarcoidosis around the world. Am. J. Med. 57:847-852.
23. Huhti, E., A. Poukkula, and M. Lilja. 1987. Prognosis for sarcoidosis in a defined geographical area. Br. J. Dis. Chest 81:381-396.
24. Hillerdal, G., E. Nou, K. Osterman, and B. Schmekel. 1984. Sarcoidosis: epidemiology and prognosis: a 15-year European study. Am. Rev. Respir. Dis. 130:29-32.
25. Newman, L. S., C. S. Rose, and L. A. Maier. 1997. Sarcoidosis. N. Engl. J. Med. 336:1224-1234.
26. Sharma, O. P. 1997. Neurosarcoidosis: a personal perspective based on the study of 37 patients. Chest 112:220-228.
27. Steffen, M., J. Petersen, M. Oldigs, A. Karmeier, B. Magnussen, H. G. Thiele, and A. Raedler. 1993. Increased secretion of tumor necrosis factor-α, interleukin-1-β and interleukin-6 by alveolar macrophages from patients with sarcoidosis. J. Allergy Clin. Immunol. 91:939-949.
28. Muller-Quernheim, J., S. Pfeifer, D. Mannel, J. Strausz, and R. Ferlinz. 1992. Lung-restricted activation of the alveolar macrophage/monocyte system in pulmonary sarcoidosis. Am. Rev. Respir. Dis. 145:187-192.
29. Bost, T. W., D. W. H. Riches, B. Schumacher, P. C. Carr, T. Z. Khan, J. A. B. Martinez, and L. S. Newman. 1994. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-α and interleukin-6, but not interleukin-1β. Am. J. Respir. Cell Mol. Biol. 10:506-513.
30. Fox, R. I. 1993. Mechanism of action of hydroxychloroquine as an antirheumatic drug, Semin. Arthritis Rheum. 23:82-91.
31. Zhu, X., W. Ertel, A. Ayala, M. H. Morrison, M. M. Perrin, and I. H. Chaudry. 1993. Chloroquine inhibits tumor necrosis factor-alpha mRNA transcription. Immunology 80:122-126.
32. Hunninghake, G. W., J. E. Gadek, R. C. Young, O. Kawanami, V. J. Ferrans, and R. G. Crystal. 1980. Maintenance of granuloma formation in pulmonary sarcoidosis by T lymphocytes within the lung. N. Engl. J. Med. 302:594-598.
33. Baumer, I., G. Zissel, M. Schlaak, and J. Muller-Quernheim. 1997. Th1/Th2 cell distribution in pulmonary sarcoidosis. Am. J. Respir. Cell Mol. Biol. 16:171-177.
34. Landewe, R. B., A. M. Miltenburg, M. J. Verdonk, C. L. Verweij, F. C. Breedveld, M. R. Daha, and B. A. Dijkmans. 1995. Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness. Clin. Exp. Immunol. 102:144-151.
35. Edmead, C. E., Y. I. Patel, A. Wilson, G. Boulougouris, N. D. Hall, S. G. Ward, and D. M. Sansom. 1996. Induction of activator protein (AP)-1 and nuclear factor-κB by CD28 stimulation involves both phosphatidylinositol 3-kinase and acidic sphingomyelinase signals. J. Immunol. 157:3290-3297.